Genitourinary Cancers | Specialty

Dr. Rini on Molecular Characteristics of the IMmotion151 Study in RCC

November 7th 2018

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the molecular characteristics of patients with renal cell carcinoma (RCC) enrolled on the IMmotion151 study.

Prodrugs in Oncology: Teaching Old and New Drugs More Tricks

November 7th 2018

As researchers gain a better understanding of the unique aspects of individual tumor types and their surrounding microenvironment, the design of novel therapies categorized as prodrugs is become increasingly sophisticated, and several novel constructs show particular promise.

Tivozanib Improves PFS in Highly Refractory RCC

November 6th 2018

The VEGF inhibitor tivozanib reduced the risk of disease progression or death by 26% compared with sorafenib in patients with highly refractory advanced or metastatic RCC, according to topline findings from the phase III TIVO-3 trial.

Dr. Meeks on Mutations Associated With T1 Progression in Bladder Cancer

November 6th 2018

Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.

Dr. Amin on Evaluating Response to Immunotherapy in RCC

November 3rd 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses methods of evaluating response to immunotherapy in renal cell carcinoma (RCC).

Frontline Paradigm Continues to Evolve in RCC

November 2nd 2018

Claud M. Grigg, Jr, MD, discusses the evolving treatment options in the frontline setting for patients with renal cell carcinoma.

Lead Investigator Highlights Pembrolizumab Potential in BCG-Resistant Bladder Cancer

November 2nd 2018

Ronald de Wit, MD, PhD, discusses the clinical implications of pembrolizumab in the non–muscle invasive bladder cancer patient population.

Dr. O'Donnell on PD-L1 Testing in Bladder Cancer

November 2nd 2018

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses PD-L1 testing in patients with bladder cancer.

Immunotherapy Combinations Taking Shape in RCC

November 1st 2018

Asim Amin, MD, discusses the current role of checkpoint inhibitors in advanced renal cell carcinoma and where the future is heading in this space.

Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCC

October 30th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses how to manage toxicities associated with immunotherapy and tyrosine kinase inhibitor combinations in renal cell carcinoma.

Dr. Grigg on the Future Treatment Landscape of Renal Cell Carcinoma

October 30th 2018

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses the future treatment landscape of renal cell carcinoma (RCC).

Dr. Sweis on Immunotherapy Combinations in Kidney Cancer

October 25th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses immunotherapy combinations in kidney cancer.

Pembrolizumab Active in BCG-Unresponsive NMIBC

October 24th 2018

An interim analysis of an ongoing single-arm open-label phase II study showed encouraging antitumor activity with pembrolizumab (Keytruda) in patients with high-risk nonmuscle invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin.

Dr. Amin on Next Steps With Immunotherapy in Advanced RCC

October 24th 2018

Asim Amin, MD, PhD, director of immunotherapy, Levine Cancer Institute, discusses next steps with immunotherapy in the treatment of patients with advanced renal cell carcinoma.

The Rapidly Changing Landscape in RCC Therapy: What Future Research May Hold

October 24th 2018

The poor long-term survival outcomes for patients with advanced renal cell carcinoma have prompted intensive clinical research aimed at developing novel therapeutic options addressing unmet needs.

Dr. Grigg on Frontline Tyrosine Kinase Inhibitors in RCC

October 23rd 2018

Claud Grigg, MD, medical oncologist, Levine Cancer Institute, discusses frontline tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC).

Higher Dose of Ipilimumab Added to Nivolumab Effective in Bladder Cancer

October 22nd 2018

Extended follow-up data from the CheckMate-032 study shows a trend toward higher overall response and longer progression-free survival with the regimen of nivolumab at 1 mg/kg plus ipilimumab at 3 mg/kg in patients with platinum-pretreated metastatic urothelial carcinoma.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Avelumab/Axitinib Nearly Doubles PFS, ORR in Frontline RCC

October 21st 2018

The combination of avelumab and axitinib doubled objective response rates and significantly improved progression-free survival compared with sunitinib in patients with treatment-naïve advanced renal cell carcinoma regardless of PD-L1 expression.

ESMO 2018: Dr. Verma Sheds Light on Breast Cancer Data

October 21st 2018